Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

German Guidelines Seek To Boost Biosimilar Uptake

Prescribers In Germany Are Asked To Factor Economic Benefits Of Biosimilars

Executive Summary

Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.

You may also be interested in...



Zolgensma First To Be Subject To New German Data Collection Rules

The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.

Germany Could Introduce Biosimilar Substitution By Pharmacists In Three Years

A German bill aims to cut spending on biologics, but new revisions mean that measures on biosimilar substitution are likely to be delayed by three years.

Improve Access to RWD In Asia To Make RWE Viable

Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.

Topics

UsernamePublicRestriction

Register

PS142970

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel